JCR Pharmaceuticals is focusing on the commercialization of Prochymal in Japan for the treatment of patients with GvHD. Chugai could be giving chase, knowing the 10 million could be returned over time for GvHD. With this in mind, the gamble is not quite that big for Chugai. The stroke results are still a big unknown, but in the event of success, would you not predict a PCYC scenario playing out with the likes of JNJ or Pfizer? If MAPC is that potent, then the sky is the limit.
Twitter, yes, that is what Gil was doing while having his coffee.
Athersys Inc athersys
Athersys and Chugai Enter License Agreement & Collaboration to Develop MultiStem® Therapy for Stroke in Japan
about an hour ago
I think you are right. More details from Athersys tomorrow.
Everyone will be sleeping easy except for the shorts!
Something tells me the press release coordination was lost in translation.
Somebody needs to call Gil and let him know that the party is on early.
Athersys website went to bed early....
Osiris Receives Milestone Payment for Prochymal Development Progress in
COLUMBIA, Md. -- April 28, 2010
Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that it has achieved
a $1 million milestone payment from its Japanese commercial partner, JCR
Pharmaceuticals, for development progress made advancing Prochymal for the
treatment of acute graft vs. host disease (GvHD) in Japan.
In 2003, Osiris formed a partnership with JCR Pharmaceuticals focusing on the
commercialization of Prochymal in Japan for the treatment of patients with
GvHD. The collaboration provides for additional milestone payments for
regulatory and sales milestones, as well as significant royalty payments on
sales of the drug in Japan.
Chugai just paid $10 million on speculation.
How will ATHX be worth $20 PPS tomorrow.
Until the results come in, we move sideways.
Still no Athersys press release on their website?
Does ATHX still own the USA stroke market?
Culturing protocols for human multipotent adult stem cells.
Culture procedures are presented that support the initiation and controlled expansion of the multipotent adult progenitor cell (MAPC) population within the human bone marrow derived multipotent mesenchymal stromal cell compartment. Culture procedures or conditions and characterization assays that maintain and survey the distinctive primitive MAPC properties are discussed in the context of cell culturing platforms that facilitate controlled expansion of clinical grade human MAPC product to levels required for mid to late stage clinical testing.
Methods Mol Biol (2015) 1235:49-58
MAPC's contribution to recovery, if any, could be very complex, or it could be one component from the cells that is responsible for the majority of the benefit. It is so complex, no one really knows what is going on.
The collective evidence from MAPC, MSC, and neural stem cells suggests that there is some benefit in model systems, including primates which is encouraging. We all know why MAPC has advantages over MSC and NSC.
However, teasing the truth of efficacy away from the noise of natural recovery and high variability associated with stroke is a tall order.
Gil and company are already in high cotton and eating gravy. First, they have lucrative salaries, second, win or lose in the stroke trial, the general consensus is that these cells do indeed have value. As seen with Osiris, even though Prochymal failed its heart attack primary outcome, Mesoblast was ready to pony up 100M. Pfizer will take MultiStem. It is just a question of, on what terms?
When we have a no lose scenario for management. A trial that fails to prove what is actually real benefit is not a problem for anyone...except shareholders. Hence, the sinking ship warning is to make only a prudent investment in ATHX.
Some have admitted on this board that they are way overextended in ATHX. I am not trying to influence anything, just calling the science and odds as I see them.
It is a big gamble with big potential. Management's position though, based on what happened at OSIR, is something to keep in mind. I would like to hear from Pfizer about the Crohn's BEFORE the stroke trial results. Right now, I feel like if the stroke fails but Pfizer actually likes the Crohn's data, they could clear the table for almost nothing upon stroke fail news and walk with all the marbles, giving Gil a position in ATHX/Pfizer. Just like the Icagen deal.
"In conclusion, human MSCs participate in the innate immune response against Gram-negative bacteria through the secretion of the antimicrobial peptide, LL-37. The secretion of this peptide is inducible with prior bacterial stimulation and has antimicrobial effect both in vitro and in vivo. Thus, human allogeneic human MSCs may be beneficial in bacterial infections because of their antimicrobial properties as well as their immunomodulatory effects."
Stem Cells. 2010 Dec; 28(12): 2229–2238.
What about lysozyme?
Are you limiting the definition of antibiotic to those compounds produced by bacteria?
Then what about penicillin which comes from a eukaryote?
Mesenchymal stem cells (MSC) have direct antimicrobial activity mediated in part by secretion of human cathelicidin hCAP-18/ LL-37. Arnold Caplan at Case Western Reserve has discussed this at many lectures. This has also been published.
Through this antimicrobial secretion, "Mesenchymal Stem cells synergizes with conventional antibiotic therapy and enhances clearance of chronic bacterial infections. The use of activated Mesenchymal stem cells enhances the effectiveness of conventional antibiotics in treatment of antibiotic-resistant microbial infections and may also help prevent the development of new antibiotic-resistant strains."
So, you are saying that Prochymal, which is MSC, has the distinct advantage of antimicrobial activity that MAPC (MultiStem) do not have?
I am betting that MAPC has similar function...Dude.
Splenic contraction and a potential release of red and white blood cells (Stewart and McKenzie, 2002). This contraction causes a release of proinflammatory immune cells, which are attracted to the brain by chemokines induced by the stroke. These peripheral immune cells could then act to increase neuroinflammation and subsequently neurodegeneration (Hausmann et al., 1998; Abraham et al., 2002).
Human bone marrow-derived MSCs possess direct antimicrobial activity, which is mediated in part by the secretion of human cathelicidin hCAP-18/ LL-37.